Please login to the form below

Not currently logged in
Email:
Password:

NHS boss resigns ahead of 'damning' report

The chief executive of Birmingham Children's Hospital has resigned with immediate effect ahead of the publication of a report by the Healthcare Commission

The chief executive of Birmingham Children's Hospital has resigned with immediate effect ahead of the publication of a report by the Healthcare Commission, which investigated the hospital after concerns were raised by its own doctors.

This week's Sunday Observer newspaper reported that the leading children's hospital is to be censured by the NHS watchdog. The Healthcare Commission will issue a highly critical report highlighting numerous failings in both quality of care and management processes.

Birmingham Children's Hospital NHS Foundation Trust chairwoman Joanna Davis confirmed that the chief Paul O'Connor has resigned and "has not been removed from his position".

The investigation, which was launched in November after the Observer obtained an internal NHS report which looked at the clinical standards at the children's hospital questioning consultants across different departments. The Observer stated the report, commissioned by the NHS Primary Care Trusts in Birmingham, found that support for surgeons undertaking kidney transplants at the hospital was poor and transplant services for children with serious liver failure were like "a third-class service [that is] putting patients at risk."

A Birmingham Children's Hospital spokeswoman said: "We can answer questions when the Healthcare Commission's report is out, but we cannot make any comments until that happens."

9th March 2009

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics